Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost

Merck & Co.  (MRK)  posted better-than-expected third quarter earnings Thursday, while lifting its full-year profit guidance for a second time, thanks in part to impressive sales of its blockbuster cancer treatment Keytruda.